NCT00483405 - Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2010

Study Completion Date

December 31, 2010

Conditions

Liver Cancer

Interventions

BIOLOGICAL

cetuximab

250 mg/m2, intravenously, once per week

DRUG

capecitabine

850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.

DRUG

oxaliplatin

130 mg/m2, intravenously on Day 1 of each 21 day cycle

Trial Locations (1)

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill